Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTekCapital Regulatory News (TEK)

Share Price Information for TekCapital (TEK)

Share Price is delayed by 15 minutes
Get Live Data
5.80    -0.10 (-1.69%)
Bid:
5.70
Ask:
5.90
Spread: 0.20 (3.509%)
Market Cap: £14.92m
TEK Live PriceLast checked at - London Stock Exchange

Intraday TekCapital Share Chart

Contract Win

10 Jun 2025 07:00

RNS Number : 0211M
GenIP PLC
10 June 2025
 

 

 

10 June 2025 

 

GenIP Plc

("GenIP" or the "Company")

 

Contract Win

 

GenIP Plc, a technology business providing Generative Artificial Intelligence (GenAI) services to help research organisations and corporations commercialise their innovations, is pleased to announce its expansion into the Republic of Chile through an engagement for 30 analytical assessment orders from a leading research institution.

 

This order increases the total value of Invention Evaluator orders received by GenIP since its IPO in October 2024 to over $850,000[1].

 

 

Melissa Cruz, CEO of GenIP, commented:

 

"I am delighted to announce another new international contract with a leading research university, marking GenIP's first entry into the Chilean market. The institution has purchased 30 Invention Evaluator assessments, to support technology commercialisation decisions across its research portfolio. This milestone strengthens GenIP's growing footprint in Latin America and underscores global demand for its GenAI-enabled services.

 

"GenIP's global expansion is underpinned by a healthy balance sheet that allows the Company to capitalise on opportunities as they arise. As outlined in our audited results, the reported Operating Loss of $888,545 included $358,924 of share-based payments relating to the IPO that are not expected to recur. Customers typically pay in advance for Invention Evaluator report orders, providing the Company with operating cash flow and future revenue visibility, with revenue recognised upon completion and delivery of the report to the client. These factors help maintain the Company's strong financial position."

 

 

 

For further information regarding GenIP, please visit https://genip.ai/, or contact:

 

GenIP Plc

Melissa Cruz, CEO 

Via Redchurch Communications

Beaumont Cornish Limited (Nominated Adviser)

Roland Cornish / Asia Szusciak / Andrew Price

 

 

Tel: +44 (0) 20 7628 3396

 

Novum Securities Limited (Broker) 

Jon Belliss

Tel: +44 (0)20 7399 9425

JBelliss@novumsecurities.com

 

 

Redchurch Communications (Financial PR)

John Casey

 

 

genip@weareredchurch.com

 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.

 

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

 

Notes to Editors

 

About GenIP

 

GenIP provides generative artificial intelligence (GenAI) analytic services to help companies, research institutions and venture funds assess and commercialise new discoveries. GenIP combines expert human technical review with GenAI algorithms to provide insightful and verified services.

 

GenIP provides two complementary platform-based services:

1. Invention Evaluator: Provides bespoke research reports that assess the market potential of new technological innovations and discoveries using AI-driven proprietary software; and

 

2. Vortechs: which is an executive recruitment platform that through advanced machine learning algorithms and natural language processing technologies assists in matching technology organisations with experienced executives skilled in technology commercialisation.

 

The Company believes that its integrated GenAI service offerings will help organisations to evaluate and commercialise their technological innovations. 

Company Strategy

GenIP's goal is to be a leading Generative AI analytic services company. To achieve this, the Company has established three strategic pillars:

 

Organically grow Invention Evaluator and Vortechs' revenue through institutional and corporate connections as well as increase client pipeline through marketing, advertising and social media spend.

Expand the Generative AI service offerings within Invention Evaluator and Vortechs' to reach new customers and improve margins.

Bolt-on acquisitions of additional Generative AI services that are helpful to our clients and have demonstrated initial market traction. 

 

 

Forward looking statements

 

Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.

 

Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".

 

For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.

-ENDS-


[1] Orders are treated as pre-payments with revenue recognised upon report production by GenIP and delivery to the client. Typically, pre-payments are utilised approximately 50% within the first 12 months and the balance over the following 12-18 months.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTUKRRRVRUNRAR
Date   Source Headline
27th May 20267:00 amRNSResults for Year Ended 31 December 2025
22nd May 20267:00 amRNSTekcapital takes stake in geothermal AI firm
21st May 20267:00 amRNSNew Orders
28th Apr 20267:00 amRNSStrategic Resale Alliance with Cardinal IP
18th Feb 20267:00 amRNSNotification of Major Holdings
10th Feb 20267:00 amRNSConditional Placing of £1.5 million
15th Jan 20267:00 amRNSCorporate Update
7th Jan 20267:00 amRNS-RPorfolio Company Update - Innovative Eyewear Inc
12th Dec 20257:00 amRNS-RPortfolio Company Update - Innovative Eyewear Inc
1st Dec 20257:00 amRNS-RPortfolio Company Update - Innovative Eyewear
19th Nov 20257:00 amRNSPortfolio Company Update - Guident Corp
13th Nov 20257:00 amRNSInnovative Eyewear Q3 Unaudited Financial Results
13th Nov 20257:00 amRNSTrading Statement
10th Nov 20257:00 amRNS-RStrategic Alliance signed with Nexscient Inc
4th Nov 20257:00 amRNS-RPortfolio Company Update - Innovative Eyewear
17th Oct 20254:15 pmRNSNotification of Major Holdings
13th Oct 20251:44 pmRNSPlacing of £0.37 Million
10th Oct 20257:00 amRNSNew Product Launch – Invention Validator
8th Oct 202510:53 amRNSReplacement - Unaudited Half-Yearly Report
7th Oct 20257:00 amRNS-RPortfolio Company Update Innovative Eyewear
6th Oct 20257:00 amRNSReplacement RNS: Half-year Report
30th Sep 20257:02 amRNSCommercial Strategy Update & New Products
30th Sep 20257:00 amRNSHalf-year Report
25th Sep 20257:00 amRNS-RPortfolio Company Update -Guident
24th Sep 20257:00 amRNSUnaudited Half Yearly Report
18th Sep 20257:00 amRNSPortfolio Company Update -Guident Proposed US IPO
10th Sep 20257:00 amRNS-RPortfolio Company Update - Innovative Eyewear
29th Aug 20257:00 amRNS-RPortfolio Company Update Guident Corp
19th Aug 20257:00 amRNS-RPortfolio Company Update - Guident Corp
15th Aug 20257:00 amRNS-RPortfolio Company Update Innovative Eyewear Q2
13th Aug 20257:00 amRNS-RPortfolio Company Update - Guident Corp
6th Aug 20257:00 amRNS-RPortfolio Company Update - Guident Corp
25th Jul 20257:00 amRNSTrading Statement
24th Jul 20257:00 amRNS-RPortfolio Company Update - Guident Corp
21st Jul 20257:00 amRNS-RPortfolio Company Update- Innovative Eyewear
27th Jun 202512:39 pmRNSResult of AGM
19th Jun 20251:06 pmRNSNotification of Major Holdings
19th Jun 202511:07 amRNSHolding(s) in Company - Replacement
19th Jun 20257:00 amRNS-RPortfolio Company Update - Guident Corp
10th Jun 20257:00 amRNSContract Win
2nd Jun 20257:02 amRNSNotice of AGM
2nd Jun 20257:00 amRNSFinal Results Year Ended 31 December Notice of AGM
2nd Jun 20257:00 amRNSFundraising of £1.25 Million
29th May 20257:00 amRNS-RPortfolio Company Update - Innovative Eyewear Inc
23rd May 20257:00 amRNSFinal Results Year Ended 31 December 2024
16th May 20257:00 amRNS-RPortfolio Company Update - Guident Corp
12th May 20257:00 amRNSPortfolio Company Update:Guident Corp Proposed IPO
6th May 20257:00 amRNSPortfolio Company Update - Innovative Eyewear Inc.
28th Apr 20257:00 amRNSPortfolio Company Update - Innovative Eyewear Inc
24th Apr 20257:00 amRNSQ1 2025 Business Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.